1st Quarter - Report

ALLERGAN USA, INC. for ALLERGAN USA, INC.

Firm
Client
Income
—
Expenses
$420,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Telecommunications TEC

Junk Fax regulations and interpretations, and rule promulgations

LobbyistCovered position, as disclosed
JAMES M. FENTON —
TED PIPER —
ASHLIE VAN METER —

Contacted: HOUSE OF REPRESENTATIVES; Federal Communications Commission (FCC); SENATE

Pharmacy PHA

Drug Labeling

LobbyistCovered position, as disclosed
JAMES M. FENTON —
TED PIPER —
ASHLIE VAN METER —

Contacted: Federal Communications Commission (FCC); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues

LobbyistCovered position, as disclosed
JAMES M. FENTON —
TED PIPER —
ASHLIE VAN METER —

Contacted: HOUSE OF REPRESENTATIVES; Federal Communications Commission (FCC); SENATE

Budget/Appropriations BUD

Deficit Reduction Act (P.L. 109-171): Medicare and Medicaid Provisions Appropriations Agriculture, Rural Development, Food and Drug Administration, and R

LobbyistCovered position, as disclosed
JAMES M. FENTON —
TED PIPER —
ASHLIE VAN METER —

Contacted: Federal Communications Commission (FCC); SENATE; HOUSE OF REPRESENTATIVES

Foreign Relations FOR

Trans-Pacific Partnership content

LobbyistCovered position, as disclosed
TED PIPER —

Contacted: HOUSE OF REPRESENTATIVES; Federal Communications Commission (FCC); SENATE

Copyright/Patent/Trademark CPT

S. 214 - Preserve Access to Affordable Generics Act;S. 504 - Fair And Immediate Release of Generic Drugs Act; patent settlements, Patent Reform bills

LobbyistCovered position, as disclosed
JAMES M. FENTON —
TED PIPER —
ASHLIE VAN METER —

Contacted: Federal Communications Commission (FCC); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 504 (113th), S. 214 (113th)

Health Issues HCR

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

LobbyistCovered position, as disclosed
JAMES M. FENTON —
TED PIPER —
ASHLIE VAN METER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Federal Communications Commission (FCC)

Bills named: H.R. 1285 (113th), S. 348 (113th), S. 504 (113th), H.R. 486 (113th), H.R. 672 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.